Virus replication in skin bacteria may amplify irritation when therapy resumes
In skin models with defined bacteria, persistent bacteriophage replication could amplify irritation after therapy resumes at unchanged drug exposure. Failure to transfer the response, together with its persistence after confirmed replication arrest, would reject the hypothesis.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Rhythm or programme
Bacteriophage replication
The process by which bacteriophages reproduce within bacteria
Where this hypothesis actsIn skin staphylococci after repeated skin restoration and during treatment resumption
Hypotheses on this target 2
Inhibition1
Activation
Function preservation
Feedback restoration
Rhythm restoration
Direct measurement
What is proposed
Inhibition
Selectively stop bacteriophage replication
With whatNot stated in the record
HowPreserve bacterial load while stopping replication; the specific intervention is not stated
Possible result
Possible prevention of amplified irritation and recurrent inflammatory complications when therapy resumes
From the recordИзбирательное прекращение фаговой репликации устраняет усиление при сохранении бактериальной нагрузки.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Repeated skin treatment could leave behind something that makes the next round more irritating, even after the drug has gone. The unexpected proposal is that this carryover comes from viruses multiplying inside skin bacteria, rather than from leftover drug or persistent deposits. This is a hypothesis generated by the pipeline, not a measured result.
- Treatment, associated skin care or the damage they cause is proposed to trigger virus multiplication inside skin bacteria.
- Virus multiplication is proposed to continue after drug removal, allowing reproducing viral material to carry the effect of earlier treatment.
- Repeated virus-driven destruction of bacteria is proposed to keep releasing substances that provoke inflammation.
- Renewed treatment is proposed to increase viral multiplication again, producing stronger irritation at the same drug exposure and with the same bacterial types and average numbers.
- Selectively stopping viral multiplication is predicted to remove the excess irritation while preserving bacterial numbers.
A garden can contain the same average number of plants while losing and replacing them much faster. Counting standing plants alone would miss the extra debris produced by that turnover.
Where the picture breaks: This picture explains how unchanged bacterial numbers could conceal more bacterial destruction. It does not establish that viruses sustain that destruction, that released material causes irritation, or that the process survives a treatment break.
- Master questionstep 01 of 04
The goal is a therapy that brings the functioning of middle-aged human skin closer to that of young skin.
Rests on: The supplied goal explicitly names the population and desired improvement, but does not specify which skin functions would define success.
Stated in the chain - Goal pillarstep 02 of 04
Limiting damage that accumulates through repeated repair is selected as one route toward better skin function.
Rests on: The goal calls for improved skin function; this stage assumes that damage from repeated repair is an obstacle to achieving it.
AssumptionThe supplied goal does not establish that repeated repair causes accumulating damage in the intended population or that limiting it restores youthful function.
- Gap questionstep 03 of 04
Stronger irritation after a treatment break might persist even at the same drug concentration in skin. The question is whether removing leftover drug prevents irritation from increasing across repeated restarts.
Rests on: The preceding stage identifies accumulating damage from repeated repair, but does not connect it specifically to treatment breaks, retained drug or increasing irritation.
LeapThe missing bridge is a stated reason to select irritation after treatment restarts, and residual drug in particular, as the concrete problem through which to investigate damage from repeated repair.
- Hypothesisstep 04 of 04
Bacteriophages, viruses that infect bacteria, are proposed to keep multiplying in skin staphylococci, a group of bacteria. Repeated bacterial destruction would release material that provokes inflammation, the tissue response to damage or threat, after drug removal; renewed treatment would increase viral multiplication and irritation even with the same bacterial types and average numbers. Removing this mechanism is predicted to stabilize SPV_11, an outcome identifier whose definition is not supplied.S8S1
Rests on: The preceding question supplies the distinction between leftover drug and a lasting change that survives its removal. Partial biological grounding comes from S8, in Antimicrobial Agents and Chemotherapy (2006), which reported drug-triggered viral multiplication inside Staphylococcus aureus, one species of staphylococcal bacteria; it did not establish persistence in skin or irritation after treatment restarts. S1, a review in Trends in Microbiology (2018) available here only as an abstract, describes inflammatory effects of substances made by that species, but does not establish inflammation caused by repeated virus-driven bacterial destruction.
Supported by literature
What is carried, and what is not. Screened sources speak to separate components: S8, in Antimicrobial Agents and Chemotherapy (2006), reports drug-triggered viral multiplication in bacteria but not lasting skin effects; S3, in Nature Biotechnology (2014), describes bacterial viruses making copies when killing a cell but not repeated treatment-associated irritation; and S1, in Trends in Microbiology (2018), describes bacterial substances provoking inflammation but not their sustained release through viral destruction. None establishes the proposed sequence from an earlier skin treatment through persistent viral multiplication to stronger irritation after a restart.S8S3S1
Where the reasoning is carried by something unstated · 2
- Goal pillar. The supplied goal does not establish that repeated repair causes accumulating damage in the intended population or that limiting it restores youthful function.
- Gap question. The missing bridge is a stated reason to select irritation after treatment restarts, and residual drug in particular, as the concrete problem through which to investigate damage from repeated repair. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Transfer of irritation with a purified virus-containing preparation could be mistaken for transfer by reproducing viruses when residual drug or soluble inflammatory substances caused the effect. What closes it: The proposed successive transfers must demonstrate infectious virus particles alongside the effect, with confirmed drug removal and dilution of the original soluble substances below concentrations that cause a response. Those effective concentrations and the criteria for successful removal are not supplied and must be established before interpreting transfer.
- Loss of irritation after an intervention intended to stop viral multiplication could instead reflect fewer bacteria or a direct reduction of inflammation by the intervention. What closes it: Stopping viral multiplication must be verified alongside preserved bacterial numbers and community composition, and controls must assess whether the intervention itself reduces inflammation. Viral deoxyribonucleic acid, or DNA, the genetic material being counted, is insufficient on its own: the proposed measurements of infectious particles and the rate of bacterial destruction are needed.
- Matching the total amount of drug before treatment resumes could conceal a later burst of active drug released from tissue binding, falsely attributing stronger irritation to viruses. What closes it: The competing drug-retention explanation requires matching where and when unbound drug and active metabolites, substances formed from the drug that retain biological activity, occur after treatment resumes. Confirming only the initial total drug amount would not separate these explanations.
What would make this wrong. In a model where the chosen treatment has first been shown to trigger viral multiplication, failure of the purified virus-containing preparation to transfer the heightened response, together with persistence of that response after verified selective cessation of viral multiplication, would contradict the hypothesis's stated predictions. Such findings require confirmed drug removal, suitable recipient bacteria and preservation of bacterial numbers so that failed transfer or an ineffective intervention is not mistaken for a failed mechanism.
What it would change. If the predicted transfer and selective removal of the effect held, repeated-treatment studies would need to account for ongoing virus-driven bacterial destruction even when bacterial counts appear unchanged. This would identify a possible route to reducing repeated inflammatory complications while pursuing better skin function. It would still not establish restoration of youthful function in middle-aged people: the initial test uses reconstructed skin, a laboratory-built skin model, and applies only after the chosen treatment or associated damage has been shown to trigger viral multiplication. The supplied material also does not define SPV_11 or connect a change in that measure to the master goal.
Sources read · 9
Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. · Trends in microbiology · 2018
“S. aureus expresses several molecules that contribute to the intensity of symptoms, including δ-toxin which stimulates mast cells, α-toxin which damages keratinocytes, phenol-soluble modulins which stimulate cytokine release by keratinocytes, protein A which triggers inflammatory responses from keratinocytes, superantigens which trigger B cell expansion and cytokine release, and proinflammatory lipoproteins.”
Does not settle: Источник не устанавливает репликацию бактериофагов в кожных стафилококках, ее сохранение после удаления препарата, связь с возобновлением терапии или усилением раздражения при одинаковом составе и численности бактериального сообщества.
Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials. · Frontiers in cellular and infection microbiology · 2022
“Phages are lytic viruses that infect bacteria from a variety of habitats, including soil, wastewater, and aquatic environments ( ).”
Does not settle: Источник не устанавливает у людей длительную репликацию бактериофагов в кожных стафилококках после восстановления кожи, повторное разрушение бактерий, воспалительные последствия после отмены препарата, усиление раздражения при возобновлении терапии или влияние на SPV_11 при одинаковом составе и численности бактериального сообщества.
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. · Nature biotechnology · 2014
“As opposed to bacteriophages, which can produce hundreds of copies of themselves when they kill a cell, our phagemid system does not produce more particles after infection.”
Does not settle: Источник не устанавливает длительную репликацию бактериофагов в кожных стафилококках, раздражение при возобновлении терапии, воспалительные последствия лизиса, сохранение эффекта при одинаковом составе сообщества и численности бактерий или влияние устранения фагов на SPV_11.
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. · Blood · 2024
“Here, we report that S aureus and staphylococcal enterotoxins (SE) induce drug resistance in malignant T cells against therapeutics commonly used in CTCL.”
Does not settle: This source does not establish bacteriophage replication in skin staphylococci, persistence after drug removal, repeated irritation on therapy resumption, comparable community composition or bacterial abundance, SPV_11 stabilization, or an inflammatory mechanism caused by phage-mediated bacterial lysis.
Transcriptional profiling of Pseudomonas aeruginosa and Staphylococcus aureus during in vitro co-culture. · BMC genomics · 2019
“Both organisms also induced lysogenic mechanisms related to prophage induction ( S. aureus ) and R- and F- pyocin synthesis ( P. aeruginosa ), possibly as a response to stress resulting from nutrient limitation or cell damage.”
Does not settle: Источник описывает транскрипционный ответ при трёхчасовом совместном культивировании P. aeruginosa и S. aureus. Он оставляет открытыми процессы в коже человека, связь с терапией и её возобновлением, длительную репликацию фагов, лизис стафилококков, воспаление, состав и численность сообщества, а также показатель SPV_11.
Characterization of Bacteria and Inducible Phages in an Intensive Care Unit. · Journal of clinical medicine · 2019
“In the event of environmental stress, functional prophages can be excised and enter a lytic cycle”
Does not settle: The source does not establish phage replication in skin staphylococci, persistence after therapy removal, recurrent treatment-associated irritation, inflammatory components, unchanged community composition or bacterial abundance, SPV_11, or effects of eliminating phages.
Characterisation of PVL-Positive Staphylococcus argenteus from the United Arab Emirates. · Antibiotics (Basel, Switzerland) · 2024
“Temperate phages contribute to the virulence properties of their bacterial hosts, and here, we describe a case in which PVL phages even crossed a species barrier, transmitting PVL genes from S. aureus into a S. argenteus lineage.”
Does not settle: Источник не устанавливает репликацию бактериофагов в кожных стафилококках у людей, её длительное сохранение после терапии, связь с раздражением при возобновлении лечения, одинаковый состав и численность бактериального сообщества или влияние устранения фагов на SPV_11.
Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. · Antimicrobial agents and chemotherapy · 2006
“Treatment of lysogens with subinhibitory concentrations of either antibiotic resulted in (i) delysogenization of strains resembling the isolates picked up after chronic lung infection and (ii) replication of phages in the bacterial host in a dose-dependent manner.”
Does not settle: Источник не устанавливает длительное сохранение фаговой репликации в коже, повторное усиление раздражения при возобновлении терапии, воспалительные последствия разрушения бактерий, одинаковый состав сообщества и численность бактерий или влияние на SPV_11.
Beta-hemolysin promotes skin colonization by Staphylococcus aureus. · Journal of bacteriology · 2013
“Genome sequencing of the Hlb-producing colonies revealed that precise excision of prophage Sa3mw occurred, leading to reconstruction of the intact hlb gene in their chromosomes.”
Does not settle: Источник не устанавливает длительную репликацию фагов, повторное разрушение бактерий, связь с возобновлением терапии или усилением раздражения при одинаковой лекарственной экспозиции.
The gap this hypothesis explains
Does restarting treatment worsen irritation at equal tissue drug levels, and does clearing leftover drug prevent worsening?
Original wording · exactly as the pipeline generated it
Сохраняется ли усиленная реакция после перерыва при одинаковой тканевой концентрации препарата, и предотвращает ли устранение остаточной экспозиции нарастание раздражения при повторном возобновлении терапии?
What this question is asking
The question concerns whether skin responds more strongly when drug treatment resumes after a break. It asks whether that stronger response remains when the amount of drug in the tissue is the same as during the earlier treatment. It also asks whether removing drug left over from earlier treatment prevents irritation from increasing across repeated restarts, compared with restarting while leftover drug remains. The wording assumes that a stronger response and progressively worsening irritation occur, but the supplied sources do not establish those patterns for the intended setting of improving skin function in middle-aged people.
- Tissue drug concentration
- The amount of a drug within a specified amount of tissue. Matching this measurement is the question's way of asking whether a stronger reaction can occur without a higher measured drug level.
- Residual exposure
- Continued exposure to drug left over from earlier treatment. The question asks whether eliminating this exposure prevents irritation from worsening; the supplied sources do not establish that it occurs in the intended setting.
- Drug clearance
- Removal of drug from the relevant tissue or body. Here, clearance means eliminating leftover drug rather than merely stopping further applications.
- Irritation
- An unwanted local reaction to treatment. The question does not specify which signs or symptoms count, how they are measured, or what would qualify as worsening.
- Inflammation
- A tissue response involving immune activity. S9 measures skin inflammation in mice; this outcome cannot automatically be treated as the same thing as treatment irritation in human skin.
- Contact sensitization
- Development of acquired allergic sensitivity to a substance that contacts the skin. It is a different outcome from irritation, so the absence reported in S1 does not settle the restart question.
- Allergic symptoms
- Symptoms attributed to an immune reaction against a substance. Their return after restarting a drug in S10 does not by itself establish stronger local irritation or increasing severity over successive restarts.
- Absorption
- Movement of an applied drug into tissue or into the wider body. Absorption studies address where drug goes, but do not necessarily establish how tissue reacts when treatment resumes.
- Psoriasis-like mouse model
- An experimental condition in mice intended to resemble aspects of psoriasis, an inflammatory skin disease. Its findings concern that model and do not directly establish the same response in human skin.
- Repeat challenge
- A renewed exposure used to provoke a response. S9 reports a repeat challenge at the same skin site, which is not enough to establish what happens during repeated restarts of the proposed therapy.
- Redistribution
- A change in where cells are located. S9 reports persistence of a redistribution pattern after withdrawal; this is not a measurement of drug remaining in tissue.
- Case report
- A description of an individual clinical case. S10 establishes what was reported in that case, without establishing how commonly the response occurs.
An enhanced response occurs after a treatment break, and irritation increases with repeated treatment restarts.
The assumption is that tissue reacts more strongly after treatment resumes and that irritation builds across successive restarts. Drug remaining in the tissue is treated as a possible contributor to that pattern. Establishing the pattern would provide the effect whose dependence on leftover drug the question asks about.
S9 reports more severe skin inflammation after a repeat challenge at the same site in previously treated mice, supporting a narrower version of a stronger response after withdrawal. S10 reports the return of allergic symptoms after one drug restart, which establishes recurrence in that case rather than progressive irritation. Neither establishes increasing irritation across repeated restarts in middle-aged human skin, and neither tests matched tissue drug levels or removal of residual exposure.S9S10
The same question asked without the part nothing read establishes:
- At the same tissue drug level, is skin irritation greater after restarting treatment than during the earlier treatment period?
- Does removing drug remaining from earlier treatment change skin irritation across repeated treatment restarts?
- Stronger response persists; clearing leftover drug prevents worsening This combination would indicate that the measured tissue drug level alone does not explain the stronger response after a break. It would also support a contribution from leftover drug to worsening across restarts, without establishing that both effects have the same cause.
- Stronger response persists; clearing leftover drug does not prevent worsening The stronger response would remain despite matching tissue drug levels. Removing leftover drug would therefore be insufficient to prevent worsening, and treating clearance as protection against irritation would be unsupported.
- Stronger response disappears; clearing leftover drug prevents worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Prevention of worsening after clearance would support a contribution from leftover exposure, although it would not establish the full mechanism.
- Stronger response disappears; clearing leftover drug does not prevent worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Failure of clearance to prevent worsening would also leave leftover drug insufficient as an explanation for any increase in irritation across restarts.
Drug remaining in tissue could contribute to exposure when treatment resumes; this is a possibility posed by the question, not a finding established by the supplied sources. If a stronger response persisted at the same tissue drug level, the measured level alone would not explain the difference. If removing leftover drug prevented worsening, that would support a contribution from continued exposure between treatment periods. Confusing these possibilities could lead to an unsupported expectation that a treatment break or drug clearance prevents irritation, while the supplied evidence also does not establish improved skin function.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Проверяемая гипотеза: у части людей повторное восстановление кожи запускает длительно сохраняющуюся репликацию бактериофагов в кожных стафилококках. Повторное разрушение бактерий поддерживает поступление воспалительных компонентов даже после удаления препарата. При возобновлении терапии очередное усиление фаговой репликации вызывает более выраженное раздражение при прежней лекарственной экспозиции. Носителем предыстории служит воспроизводящийся вирусный материал. Механизм предполагает сохранение эффекта при одинаковых составе бактериального сообщества и средней численности бактерий. Его устранение должно стабилизировать SPV_11, ограничивая повторные воспалительные осложнения.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
В колонизированных моделях кожи усиленный ответ сохраняется после подтверждённого удаления препарата. Очищенная фаговая фракция переносит способность к усиленному ответу в ранее не подвергавшуюся терапии модель с теми же бактериями; эффект воспроизводится при последовательном переносе через новые культуры после разведения исходных растворимых медиаторов ниже действующих концентраций. Избирательное прекращение фаговой репликации устраняет усиление при сохранении бактериальной нагрузки. Удаление кристаллов холестерина эффекта не устраняет. Отсутствие переноса и сохранение реакции после подтверждённого прекращения репликации опровергают гипотезу.
Would tell it apart from at least one rival. The prediction specifies observable persistence and intervention outcomes, plus an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Первичная проверка возможна в реконструированной коже с заданным бактериальным составом. Нужны измерения инфекционных фаговых частиц, скорости разрушения бактерий, жизнеспособности кератиноцитов и воспалительного ответа. Число копий вирусной ДНК само по себе не доказывает репликацию. Применимость ограничена режимами, для которых сначала показана индукция фагов используемым препаратом, сопутствующим уходом или вызванным ими повреждением.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
В колонизированных моделях кожи усиленный ответ сохраняется после подтверждённого удаления препарата. Очищенная фаговая фракция переносит способность к усиленному ответу в ранее не подвергавшуюся терапии модель с теми же бактериями; эффект воспроизводится при последовательном переносе через новые культуры после разведения исходных растворимых медиаторов ниже действующих концентраций. Избирательное прекращение фаговой репликации устраняет усиление при сохранении бактериальной нагрузки. Удаление кристаллов холестерина эффекта не устраняет. Отсутствие переноса и сохранение реакции после подтверждённого прекращения репликации опровергают гипотезу.
- Rival 01 of 02What would separate them
Retained cholesterol crystal seeds may amplify skin inflammation after repeated damage and repair predicts: В стерильных моделях кожи при повторных одинаковых воздействиях усилению ответа предшествует появление кристаллического холестерина. Устранение подтверждённых кристаллов с восстановлением прежнего общего содержания холестерина в некристаллической форме отменяет усиление. Внесение малой массы кристаллических зародышей возвращает его, тогда как равная масса некристаллического холестерина этого не делает. После удаления всех зародышей время до повторного возникновения эффекта становится случайным и зависит от объёма восприимчивой ткани; при сохранённых зародышах задержка сокращается. Сохранение усиления после устранения кристаллов при неизменной жизнеспособности опровергает гипотезу.
- Rival 02 of 02What would separate them
Competition for tissue binding sites may release retained drug and worsen skin irritation predicts: После первого курса с изотопно меченным препаратом нанесение основы без новой дозы действующего вещества вызывает кратковременное повышение свободной меченой формы и раздражение. Эффект зависит от способности компонентов основы вытеснять препарат в независимом опыте связывания. После удаления связанного остатка всплеск исчезает; его воспроизведение в ранее не обработанной ткани воспроизводит выраженность повреждения. При одинаковых полных профилях свободной активной формы ранее обработанная и контрольная кожа отвечают одинаково. Сохраняющееся различие после такого выравнивания опровергает гипотезу в пользу самостоятельного носителя предыстории.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
В опытах с Staphylococcus aureus меньшая концентрация ципрофлоксацина сопровождалась более выраженным фагозависимым уничтожением персистирующих бактерий; подавление индукции профага устраняло этот немонотонный эффект. Это показывает возможность усиления биологического последствия при снижении лекарственной концентрации, но не доказывает кожную гипотезу. [Первичное исследование](https://pubmed.ncbi.nlm.nih.gov/26593926/).
Клиническая дерматофармакология, учебная глава «Контактный дерматит и нежелательные реакции на наружные препараты». Подтверждение потребует включить передаваемую вирусную репликацию в число самостоятельных носителей сохраняющейся повышенной реактивности после отмены препарата.
Предыстория раздражения передаётся между независимыми моделями кожи через очищенные реплицирующиеся бактериофаги без переноса клеток человека, остаточного препарата или изменённого бактериального сообщества.
Выполненный целевой поиск не обнаружил работы, утверждающей именно перенос лекарственно обусловленной повышенной реактивности очищенной фаговой фракцией при одинаковом бактериальном составе и удалённом препарате. Общая связь кожного вирома с воспалением уже обсуждается и новизной не является. Отсутствие такой гипотезы во всей литературе не доказано; статус HERETICAL предварительный.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.